Subjective experience and dopamine D2 receptor occupancy in patients treated with antipsychotics: clinical implications.
about
Hyperactivation balances sensory processing deficits during mood induction in schizophreniaAntidepressant-like effect of D(2/3) receptor-, but not D(4) receptor-activation in the rat forced swim test.Substance abuse in patients with schizophrenia.Is neuroleptic dysphoria a variant of drug-induced extrapyramidal side effects?Striatal D(2/3) Binding Potential Values in Drug-Naïve First-Episode Schizophrenia Patients Correlate With Treatment Outcome.Behavioral and emotional adverse events of drugs frequently used in the treatment of bipolar disorders: clinical and theoretical implications.AMPT-induced monoamine depletion in humans: evaluation of two alternative [123I]IBZM SPECT procedures.Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging.Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophreniaSubjective well-being in schizophrenia as measured with the Subjective Well-Being under Neuroleptic Treatment scale: a review.Treatment for Negative Symptoms in Schizophrenia: A Comprehensive Review.Therapeutic drug monitoring of second-generation antipsychotics in pediatric patients: an observational study in real-life settings.Psychopharmacological treatment for schizophrenia: less is more.Second-generation antipsychotics: looking beyond efficacy.Blockade of 5-HT2a receptors reduces haloperidol-induced attenuation of reward.Use of antipsychotic medication and suicidality--the Northern Finland Birth Cohort 1966.No Effect of Dose Adjustment to the Genotype in Patients With Severe Mental Illness
P2860
Q30420000-B4C499CC-E00D-4465-8009-519B7BDC08FCQ34390424-ADC4D69A-8BF1-4EE4-9E9E-06D66B7BD598Q35236689-0C4C0799-7FFD-43D9-BCF0-E056A481BB34Q35805886-C00CFCB8-C1AA-49F2-B93E-59CCD7732336Q35950793-F0D6C0D8-A24C-4401-885D-BD61E4A25DA0Q36582018-8F781746-DCD2-4296-88DE-7D14B64B0008Q36738339-89F61986-8A54-4F98-903E-A646558FE6C4Q36941951-E3291F26-2FED-4C94-A17D-C13C7D24C206Q37315451-C0587078-C29E-4940-BA1F-74EE165472C4Q37857856-3DE63651-005D-4755-9EA1-83D77E009186Q38647035-4295F983-29DA-4DA5-869D-3C4CCA44AFD2Q40267262-1B2415F6-41D1-4D11-99F3-8AA7877CBAFDQ41078277-FA4F8AEF-6EA4-4060-98D4-73694494180AQ44937604-79A4A550-5A7D-4057-BD0C-BB5B78CBCA30Q48489442-6D4B3620-787C-481E-9D85-40DCC95398CBQ48628524-7BCC7E30-0D40-4EB4-A115-D5F69106E36CQ58797266-ACEF4341-2300-4E5B-8B7D-F7B72AD132A7
P2860
Subjective experience and dopamine D2 receptor occupancy in patients treated with antipsychotics: clinical implications.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Subjective experience and dopa ...... hotics: clinical implications.
@ast
Subjective experience and dopa ...... hotics: clinical implications.
@en
type
label
Subjective experience and dopa ...... hotics: clinical implications.
@ast
Subjective experience and dopa ...... hotics: clinical implications.
@en
prefLabel
Subjective experience and dopa ...... hotics: clinical implications.
@ast
Subjective experience and dopa ...... hotics: clinical implications.
@en
P2093
P2860
P50
P1476
Subjective experience and dopa ...... hotics: clinical implications.
@en
P2093
Don Linszen
Jules Lavalaye
Lonneke van Nimwegen
Marion van Bruggen
Therese van Amelsvoort
P2860
P304
P356
10.1177/070674370404900503
P407
P577
2004-05-01T00:00:00Z